Urologix (ULGX) 0.0012 $ULGX Urologix Announces
Post# of 273254
Posted On: 09/22/2016 1:18:08 AM
Urologix (ULGX) 0.0012 $ULGX
Urologix Announces Sale of Operating Assets to Private Company Buyer
GlobeNewswire - Tue Feb 02, 3:06PM CST
Urologix, Inc. (OTC Pink:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today that as of the close of business on January 29, 2015 substantially all of the operating assets of Urologix, Inc. including the Urologix name were surrendered to a secured creditor and subsequently purchased by a private company to partially address the secured debt owed to the secured creditor. The sale of Urologix's operating assets was contemplated by a forbearance agreement entered into with the secured creditor on December 7, 2015. The buyer will operate the existing business through an entity named "Urologix, LLC."
Global Prostrate Specific Antigen (PSA) Testing Market Analysis 2015-2020 - Free PSA Test, Complex PSA Test, Reverse PCR Test
M2 - Thu Sep 10, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n53fd7/prostrate) has announced the addition of the "Prostrate Specific Antigen (PSA) Testing Market Analysis (2015 - 2020); By Type (Free PSA Test, Complex PSA Test, Reverse PCR Test); By Geography (North America, Europe, APAC)" report to their offering. The PSA testing is gaining popularity among clinicians and hospitals as the number of people affected by prostate cancer in the age bracket of 40-50 years is on a rise. A high level of PSA is an indicator of possible prostate cancer. However, there are other physical conditions which might lead to an increase in PSA levels. The number of people affected by prostate cancer in 2014 was 233,000 from 417,000 in 2012. The reason for this sharp decline in prostate cancer incidences is due to effective PSA testing. The global PSA testing market was close to $250 million in 2014. The population in the age bracket of 50-64 years are more likely to develop prostate cancer. Prostate Cancer is the fourth most common cancer. The need for PSA testing has seen an upward surge. The North America region is going to see the highest increase due to better focus on healthcare. The Europe region has different guidelines and policies for PSA testing in different countries. Such scenario has led to a decreased use of PSA testing in Europe region. Market size and forecast is provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the PSA testing market and future opportunities are provided in the report. This report on the global PSA testing market identifies many such insights and M&A opportunities, besides providing a detailed analysis of the PSA testing market. Key Topics Covered: 1. PSA Testing Market Overview 2. Executive Summary 3. PSA Testing Market Landscape 4. PSA Testing Market Forces 5. PSA Testing Market - Strategic Analysis 6. PSA Testing Market - By Type 7. Global PSA Testing Market - Geographic Analysis 8. Market Entropy 9. Company Profiles (Overview, Financials, SWOT Analysis - Top 5 Companies, Developments, Product Portfolio) 10. Appendix Companies Mentioned - Abbott Laboratories, Inc. - Bayer AG - Beckman Coulter, Inc. - GE Helathcare - GlaxoSmithKline, plc. - Novartis Pharma AG. - UroLogix, Inc. - Bristol - Myers Squibb Company - AstraZeneca plc. - Johnson & Johnson Diagnostics - BioChem Pharma - Pharmacia Delfia - Roche Diagnostics - Olympus - Tosho For more information visit http://www.researchandmarkets.com/research/n53fd7/prostrate
JNJ: 118.91 (+0.96), ABT: 41.92 (+0.34), AZN: 33.75 (+0.10), GSK: 43.21 (+0.15), NVS: 81.52 (+0.46)
Urologix Announces SEC Deregistration
GlobeNewswire - Thu Jul 09, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission (the "SEC"
. The Company also intends to cause its common stock to cease trading on the OTCQB and commence trading on the OTC Pink marketplace. For more information about the OTC Pink marketplace, please see www.otcmarkets.com.
Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans
GlobeNewswire - Thu May 21, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data highlighting the costs and outcomes of cooled high energy Transurethral Microwave Therapy (HE-TUMT), Transurethral Needle Ablation (TUNA), and the Prostatic Urethral Lift (PUL) were the topic of a podium presentation this past weekend at the American Urological Association (AUA) 2015 Annual Meeting held in New Orleans, LA.
Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans
GlobeNewswire - Tue May 12, 3:01PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an upcoming presentation at the American Urological Association (AUA) 2015 annual meeting to be held May 15-18, 2015 in New Orleans, LA.
Urologix Announces Hiring of Chief Financial Officer
GlobeNewswire - Mon Mar 23, 8:00AM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the appointment of Scott M. Madson as its Chief Financial Officer effective April 1, 2015. Mr. Madson brings over 30 years of both public and private company financial leadership experience to his new role, having most recently provided finance and accounting management consulting services through his company, Madson Consulting LLC. Previously, Scott was Vice President, Controller and Chief Accounting Officer for Universal Hospital Services, Inc, one of the nation's largest providers of mobile medical equipment and healthcare technology management services.
Urologix to Host Its Fiscal Year 2015 Second Quarter Conference Call
GlobeNewswire - Thu Jan 29, 3:00PM CST
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present second quarter fiscal year 2015 results on Thursday, February 5, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-515-2910 and enter the Participant Passcode 37953871 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Urologix to Host Its Fiscal Year 2015 First Quarter Conference Call
GlobeNewswire - Tue Oct 28, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present first quarter fiscal year 2015 results on Tuesday, November 4, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-318-8617 and enter the Participant Passcode 57661939 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Urologix Announces Sale of Operating Assets to Private Company Buyer
GlobeNewswire - Tue Feb 02, 3:06PM CST
Urologix, Inc. (OTC Pink:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, announced today that as of the close of business on January 29, 2015 substantially all of the operating assets of Urologix, Inc. including the Urologix name were surrendered to a secured creditor and subsequently purchased by a private company to partially address the secured debt owed to the secured creditor. The sale of Urologix's operating assets was contemplated by a forbearance agreement entered into with the secured creditor on December 7, 2015. The buyer will operate the existing business through an entity named "Urologix, LLC."
Global Prostrate Specific Antigen (PSA) Testing Market Analysis 2015-2020 - Free PSA Test, Complex PSA Test, Reverse PCR Test
M2 - Thu Sep 10, 4:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n53fd7/prostrate) has announced the addition of the "Prostrate Specific Antigen (PSA) Testing Market Analysis (2015 - 2020); By Type (Free PSA Test, Complex PSA Test, Reverse PCR Test); By Geography (North America, Europe, APAC)" report to their offering. The PSA testing is gaining popularity among clinicians and hospitals as the number of people affected by prostate cancer in the age bracket of 40-50 years is on a rise. A high level of PSA is an indicator of possible prostate cancer. However, there are other physical conditions which might lead to an increase in PSA levels. The number of people affected by prostate cancer in 2014 was 233,000 from 417,000 in 2012. The reason for this sharp decline in prostate cancer incidences is due to effective PSA testing. The global PSA testing market was close to $250 million in 2014. The population in the age bracket of 50-64 years are more likely to develop prostate cancer. Prostate Cancer is the fourth most common cancer. The need for PSA testing has seen an upward surge. The North America region is going to see the highest increase due to better focus on healthcare. The Europe region has different guidelines and policies for PSA testing in different countries. Such scenario has led to a decreased use of PSA testing in Europe region. Market size and forecast is provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining growth of the PSA testing market and future opportunities are provided in the report. This report on the global PSA testing market identifies many such insights and M&A opportunities, besides providing a detailed analysis of the PSA testing market. Key Topics Covered: 1. PSA Testing Market Overview 2. Executive Summary 3. PSA Testing Market Landscape 4. PSA Testing Market Forces 5. PSA Testing Market - Strategic Analysis 6. PSA Testing Market - By Type 7. Global PSA Testing Market - Geographic Analysis 8. Market Entropy 9. Company Profiles (Overview, Financials, SWOT Analysis - Top 5 Companies, Developments, Product Portfolio) 10. Appendix Companies Mentioned - Abbott Laboratories, Inc. - Bayer AG - Beckman Coulter, Inc. - GE Helathcare - GlaxoSmithKline, plc. - Novartis Pharma AG. - UroLogix, Inc. - Bristol - Myers Squibb Company - AstraZeneca plc. - Johnson & Johnson Diagnostics - BioChem Pharma - Pharmacia Delfia - Roche Diagnostics - Olympus - Tosho For more information visit http://www.researchandmarkets.com/research/n53fd7/prostrate
JNJ: 118.91 (+0.96), ABT: 41.92 (+0.34), AZN: 33.75 (+0.10), GSK: 43.21 (+0.15), NVS: 81.52 (+0.46)
Urologix Announces SEC Deregistration
GlobeNewswire - Thu Jul 09, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced its decision to terminate and suspend the registration of its stock with the Securities and Exchange Commission (the "SEC"
. The Company also intends to cause its common stock to cease trading on the OTCQB and commence trading on the OTC Pink marketplace. For more information about the OTC Pink marketplace, please see www.otcmarkets.com. Costs for In-Office BPH Therapies Presented at the AUA 2015 Annual Meeting in New Orleans
GlobeNewswire - Thu May 21, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX), a market leader for the in-office treatment of benign prostatic hyperplasia (BPH) today announced that data highlighting the costs and outcomes of cooled high energy Transurethral Microwave Therapy (HE-TUMT), Transurethral Needle Ablation (TUNA), and the Prostatic Urethral Lift (PUL) were the topic of a podium presentation this past weekend at the American Urological Association (AUA) 2015 Annual Meeting held in New Orleans, LA.
Urologix Products Featured in Cost-Effectiveness Research to be Presented at Upcoming Industry Meeting in New Orleans
GlobeNewswire - Tue May 12, 3:01PM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced an upcoming presentation at the American Urological Association (AUA) 2015 annual meeting to be held May 15-18, 2015 in New Orleans, LA.
Urologix Announces Hiring of Chief Financial Officer
GlobeNewswire - Mon Mar 23, 8:00AM CDT
Urologix, Inc. (OTCQB:ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced the appointment of Scott M. Madson as its Chief Financial Officer effective April 1, 2015. Mr. Madson brings over 30 years of both public and private company financial leadership experience to his new role, having most recently provided finance and accounting management consulting services through his company, Madson Consulting LLC. Previously, Scott was Vice President, Controller and Chief Accounting Officer for Universal Hospital Services, Inc, one of the nation's largest providers of mobile medical equipment and healthcare technology management services.
Urologix to Host Its Fiscal Year 2015 Second Quarter Conference Call
GlobeNewswire - Thu Jan 29, 3:00PM CST
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present second quarter fiscal year 2015 results on Thursday, February 5, 2015 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-515-2910 and enter the Participant Passcode 37953871 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
Urologix to Host Its Fiscal Year 2015 First Quarter Conference Call
GlobeNewswire - Tue Oct 28, 3:00PM CDT
Urologix, Inc. (OTCQB:ULGX) will host a conference call to present first quarter fiscal year 2015 results on Tuesday, November 4, 2014 at 4:00 p.m. CT, following the Company's post-market press release on the same day. On the day of the call, please dial 1-866-318-8617 and enter the Participant Passcode 57661939 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call.
(0)
(0)Scroll down for more posts ▼